Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
暂无分享,去创建一个
C. Sander | N. Schultz | H. Scher | N. Mitsiades | C. Sawyers | M. Fleisher | D. Danila | B. He | V. Eedunuri | C. Sung
[1] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[2] J. Richie,et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. , 2012 .
[3] Barry M. Twenter,et al. Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. , 2012, Bioorganic & medicinal chemistry letters.
[4] H. Scher,et al. ARN-509: a novel antiandrogen for prostate cancer treatment. , 2012, Cancer research.
[5] Barry M. Twenter,et al. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. , 2012, Journal of medicinal chemistry.
[6] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[7] F. Saad,et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. McCombie,et al. Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis. , 2012, Journal of Clinical Oncology.
[9] N. Mitsiades,et al. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer , 2012, Expert review of anticancer therapy.
[10] W. McCombie,et al. Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis. , 2012, Journal of Clinical Oncology.
[11] P. Nelson,et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.
[12] P. Nelson,et al. Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.
[13] Rui Li,et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer , 2011, Proceedings of the National Academy of Sciences.
[14] E. Antonarakis,et al. Expanding treatment options for metastatic prostate cancer. , 2011, The New England journal of medicine.
[15] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[16] D. Tsavachidou,et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: Apreliminary report. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Yi Jin,et al. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights , 2011, The Journal of Steroid Biochemistry and Molecular Biology.
[18] C. Schmidt. Abiraterone and MVD3100 take androgen deprivation to a new level. , 2011, Journal of the National Cancer Institute.
[19] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[20] J. Humm,et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.
[21] S. Larson,et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Kantoff,et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] G. Jenster,et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. , 2010, Cancer research.
[24] H. Scher,et al. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.
[25] M. Dowsett,et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[27] Trevor M Penning,et al. Steroid Hormone Transforming Aldo‐Keto Reductases and Cancer , 2009, Annals of the New York Academy of Sciences.
[28] D. Ghosh,et al. Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation. , 2008, Biostatistics.
[29] Mitch Dowsett,et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Gleave,et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.
[31] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[32] G. Pelletier. Expression of steroidogenic enzymes and sex-steroid receptors in human prostate. , 2008, Best practice & research. Clinical endocrinology & metabolism.
[33] F. Labrie,et al. Androgen biosynthetic pathways in the human prostate. , 2008, Best practice & research. Clinical endocrinology & metabolism.
[34] P. Nelson,et al. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.
[35] T. Penning,et al. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. , 2008, Biochemical pharmacology.
[36] P. Nelson,et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.
[37] P. Nelson,et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. , 2006, The Journal of clinical endocrinology and metabolism.
[38] T. Golub,et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.
[39] J. Isaacs,et al. Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers , 2006, Clinical Cancer Research.
[40] T. Golub,et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.
[41] 宁北芳,et al. 疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .
[42] Kota Takahashi,et al. The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer , 2004, Clinical Cancer Research.
[43] W. Gerald,et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. , 2004, Endocrine-related cancer.
[44] Desok Kim,et al. The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.
[45] E. Latulippe,et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.
[46] M. Gleave,et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. , 2001, The Journal of urology.
[47] F. S. French,et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.
[48] K. Bélanger,et al. Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule , 1999 .
[49] N. Vogelzang. Comprehensive Textbook of Genitourinary Oncology , 1996 .
[50] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[51] J. Geller,et al. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. , 1984, The Journal of urology.
[52] M. Sherman,et al. A Preliminary Report , 1953 .